ODM-208 + midazolam

ODM-208 + midazolam is a combination of **ODM-208**, a novel, oral, non-steroidal, and selective inhibitor of cytochrome P450 11A1 (CYP11A1), and **midazolam**, a well-known short-acting benzodiazepine. ODM-208 blocks the first and rate-limiting step in steroid hormone biosynthesis, greatly suppressing androgen and other steroid hormone production, which is particularly relevant for the treatment of metastatic castration-resistant prostate cancer (mCRPC), notably in patients with activating androgen receptor mutations[1][2][3][4][5]. Midazolam is often used in clinical research as a probe substrate for cytochrome P450 3A (CYP3A4) metabolic activity and is not part of ODM-208’s therapeutic intervention[1][2]. The combination is likely used in pharmacokinetic drug-drug interaction studies to assess whether ODM-208 affects midazolam metabolism via CYP3A, but not as a fixed-dose combination for therapy.